Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 10 May, 2021. Please click to review the
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 10 May, 2021. Please click to review the
Imagion Biosystems is pleased to announce a partnership with the ASX-listed therapeutic antibody development company Patrys Limited. The collaborative research program aims to combine Imagion Biosystems
Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study
Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 March 2021 (Q1 FY2021). Q1
TAKE NOTICE that the Annual General Meeting of Shareholders of the Company will be held at the time, date and place specified below: Time: 10.00
Imagion Biosystems is pleased to provide its investors with its March 2021 Investor Newsletter. The newsletter details recent new company developments and activities, including: Message
Imagion Biosystems is pleased to announce it is a proud recipient of an Innovations Connections grant from the Australian Government’s Department of Industry, Science, Energy
2020 Highlights: MagSense® HER2 breast cancer Phase I study initiated Collaboration with Siemens Healthineers explores MagSense® nanoparticles using MRI Total of A$12.2 million funds raised
Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 December 2020 (Q4 FY2020). Q4
Imagion Biosystems is pleased to provide its investors with its December 2020 Investor Newsletter. The newsletter details recent new company developments and activities including: Message from
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance